NYSE
IQV

IQVIA Holdings Inc

Diagnostics & Research
Healthcare

Prices are adjusted according to historical splits.

IQVIA Holdings Inc Stock Price

Vitals

Today's Low:
$213.56
Today's High:
$219.28
Open Price:
$214.8
52W Low:
$165.75
52W High:
$241.86
Prev. Close:
$215.33
Volume:
985673

Company Statistics

Market Cap.:
$39.43 billion
Book Value:
31.393
Revenue TTM:
$14.68 billion
Operating Margin TTM:
13.17%
Gross Profit TTM:
$5.03 billion
Profit Margin:
7.47%
Return on Assets TTM:
4.79%
Return on Equity TTM:
19.75%

Company Profile

IQVIA Holdings Inc had its IPO on 2013-05-09 under the ticker symbol IQV.

The company operates in the Healthcare sector and Diagnostics & Research industry. IQVIA Holdings Inc has a staff strength of 87,000 employees.

Stock update

Shares of IQVIA Holdings Inc opened at $214.8 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $213.56 - $219.28, and closed at $216.77.

This is a +0.67% increase from the previous day's closing price.

A total volume of 985,673 shares were traded at the close of the day’s session.

In the last one week, shares of IQVIA Holdings Inc have slipped by -3.37%.

IQVIA Holdings Inc's Key Ratios

IQVIA Holdings Inc has a market cap of $39.43 billion, indicating a price to book ratio of 7.2438 and a price to sales ratio of 2.7057.

In the last 12-months IQVIA Holdings Inc’s revenue was $14.68 billion with a gross profit of $5.03 billion and an EBITDA of $2.63 billion. The EBITDA ratio measures IQVIA Holdings Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, IQVIA Holdings Inc’s operating margin was 13.17% while its return on assets stood at 4.79% with a return of equity of 19.75%.

In Q2, IQVIA Holdings Inc’s quarterly earnings growth was a positive 18.7% while revenue growth was a positive 5.3%.

IQVIA Holdings Inc’s PE and PEG Ratio

Forward PE
18.5874
Trailing PE
37.9102
PEG
1.4751

Its diluted EPS in the last 12-months stands at $5.68 per share while it has a forward price to earnings multiple of 18.5874 and a PEG multiple of 1.4751. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into IQVIA Holdings Inc’s profitability.

IQVIA Holdings Inc stock is trading at a EV to sales ratio of 3.4965 and a EV to EBITDA ratio of 17.3877. Its price to sales ratio in the trailing 12-months stood at 2.7057.

IQVIA Holdings Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$26.04 billion
Total Liabilities
$6.54 billion
Operating Cash Flow
$-596000000.00
Capital Expenditure
$160 million
Dividend Payout Ratio
0%

IQVIA Holdings Inc ended 2024 with $26.04 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $26.04 billion while shareholder equity stood at $5.75 billion.

IQVIA Holdings Inc ended 2024 with $367.00 million in deferred long-term liabilities, $6.54 billion in other current liabilities, 10952000000.00 in common stock, $3.92 billion in retained earnings and $14.18 billion in goodwill. Its cash balance stood at $1.38 billion and cash and short-term investments were $1.49 billion. The company’s total short-term debt was $1,344,000,000 while long-term debt stood at $12.43 billion.

IQVIA Holdings Inc’s total current assets stands at $5.33 billion while long-term investments were $107.00 million and short-term investments were $110.00 million. Its net receivables were $3.18 billion compared to accounts payable of $3.01 billion and inventory worth $179.00 million.

In 2024, IQVIA Holdings Inc's operating cash flow was $-596000000.00 while its capital expenditure stood at $160 million.

Comparatively, IQVIA Holdings Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$216.77
52-Week High
$241.86
52-Week Low
$165.75
Analyst Target Price
$250.84

IQVIA Holdings Inc stock is currently trading at $216.77 per share. It touched a 52-week high of $241.86 and a 52-week low of $241.86. Analysts tracking the stock have a 12-month average target price of $250.84.

Its 50-day moving average was $220.33 and 200-day moving average was $210.86 The short ratio stood at 2.61 indicating a short percent outstanding of 0%.

Around 88.6% of the company’s stock are held by insiders while 9094.3% are held by institutions.

Frequently Asked Questions About IQVIA Holdings Inc

The stock symbol (also called stock or share ticker) of IQVIA Holdings Inc is IQV

The IPO of IQVIA Holdings Inc took place on 2013-05-09

Similar Industry Stocks (Diagnostics & Research)

Last Price
Chg
Chg%
$24.29
-0.17
-0.7%
$1350.3
-16.4
-1.2%
$21.38
-0.26
-1.2%
$0.01
-0
-6.77%
Utime Ltd (UTME)
$0.37
0.01
+3.9%
$401.8
-2.4
-0.59%
$15.83
0.35
+2.26%
$28.3
-0.01
-0.04%
$9.23
-0.07
-0.75%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and decentralized clinical trials, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was incorporated in 2016 and is headquartered in Durham, North Carolina.

Address

4820 Emperor boulevard, Durham, NC, United States, 27703